Arcturus Enterprise Value over EBITDA from 2010 to 2024
| ARCT Stock | USD 26.32 1.32 4.78% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (437.48) | Current Value (415.61) | Quarterly Volatility 147.56357754 |
Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 530 K or Selling General Administrative of 55.5 M, as well as many exotic indicators such as Price To Sales Ratio of 5.06, Dividend Yield of 0.0 or PTB Ratio of 3.17. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
Arcturus | Enterprise Value over EBITDA |
About Arcturus Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Arcturus Therapeutics income statement, its balance sheet, and the statement of cash flows. Arcturus Therapeutics investors use historical funamental indicators, such as Arcturus Therapeutics's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may use each financial statement separately, they are all related. The changes in Arcturus Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Arcturus Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Arcturus Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Arcturus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company was founded in 2013 and is headquartered in San Diego, California. Arcturus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.
Pair Trading with Arcturus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arcturus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcturus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Arcturus Stock
| 0.64 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to Arcturus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arcturus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arcturus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arcturus Therapeutics Holdings to buy it.
The correlation of Arcturus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arcturus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arcturus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arcturus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Arcturus Therapeutics Correlation against competitors. Note that the Arcturus Therapeutics information on this page should be used as a complementary analysis to other Arcturus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Arcturus Stock analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| CEOs Directory Screen CEOs from public companies around the world |
Is Arcturus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 6.264 | Quarterly Revenue Growth (0.81) | Return On Assets (0.11) | Return On Equity (0.11) |
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.